

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REC'D UCPTO 13 MAR 2006 PCT  
#10  
*With  
See*

In re Patent Application of **DAL POZZO**  
Serial No. 10/522,268  
Filed: January 25, 2005  
Title: FLUORO-ALKYL-CYCLOPEPTIDE DERIVATIVES ENDOWED WITH ANTI-INTEGRIN ACTIVITY

Atty Dkt. 2818-2271 TC/A.U. unknown  
C# M#  
Examiner: Unknown  
Date: March 13, 2006

**O E**  
**MAR 13 2006**  
**PATENT & TRADEMARK OFFICE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Correspondence Address Indication Form Attached.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number	
previously paid for	20	(at least 20) =	0 x \$50.00
			\$0.00 (1202)/\$0.00 (2202) \$

Independent claims after amendment	0	minus highest number	
previously paid for	3	(at least 3) =	0 x \$200.00
			\$0.00 (1201)/\$0.00 (2201) \$

If proper multiple dependent claims now added for first time, (ignore improper); add  
\$360.00 (1203)/\$180.00 (2203) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this  
 paper and attachment(s)  
 One Month Extension \$120.00 (1251)/\$60.00 (2251)  
 Two Month Extensions \$450.00 (1252)/\$225.00 (2252)  
 Three Month Extensions \$1020.00 (1253)/\$510.00 (2253)  
 Four Month Extensions \$1590.00 (1254)/\$795.00 (2254)  
 Five Month Extensions \$2160.00 (1255)/\$1080.00 (2255) \$

Terminal disclaimer enclosed, add  
\$130.00 (1814) / \$65.00 (2814) \$

Applicant claims "small entity" status.  Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee  
\$180.00 (1806) \$

Assignment Recording Fee  
\$40.00 (8021) \$


Other:  
\$

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor  
Arlington, Virginia 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:pp

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

06/05/2006 BCAMPBEL 00000005 141140 10522268  
01 FC:1255 2040.00 DA

1051903



2818-227

BJS

Page 1 of 2

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/522,268	Dal Pozzo	2818-227

INTERNATIONAL APPLICATION NO.

PCT/IT03/00446

I.A. FILING DATE	PRIORITY DATE
07/18/2003	07/29/2002

23117  
NIXON & VANDERHYE, PC  
901 NORTH GLEBE ROAD, 11TH FLOOR  
ARLINGTON, VA 22203

CONFIRMATION NO. 8815

## 371 FORMALITIES LETTER



\*OC000000018038774\*

Date Mailed: 02/13/2006

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

i-MO. (NOT EXT.)  
DOCKETED

- Priority Document
- Copy of the International Application filed on 01/25/2005
- Copy of the International Search Report filed on 01/25/2005
- Copy of IPE Report filed on 01/25/2005
- Preliminary Amendments filed on 01/25/2005
- Information Disclosure Statements filed on 01/25/2005
- Biochemical Sequence Diskette filed on 09/26/2005
- Oath or Declaration filed on 01/25/2005
- Biochemical Sequence Listing filed on 09/26/2005
- Request for Immediate Examination filed on 01/25/2005
- Copy of references cited in ISR filed on 01/25/2005
- U.S. Basic National Fees filed on 01/25/2005
- Assignment filed on 01/25/2005
- Priority Documents filed on 01/25/2005
- Power of Attorney filed on 01/25/2005

CLT/MATTER # 2818-227  
MAIL DATE 2/13/06  
FINAL DUE DATE March 13, 2006  
FINAL DEADLINE   
DOCKETED BY DL/J

Applicant's response filed 09/26/2005 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 06/27/2005 have not been completed.

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this

**Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

---

Telephone: (703) 308-9140 EXT 217

**PART 1 - ATTORNEY/APPLICANT COPY**

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/522,268	PCT/IT03/00446	2818-227

FORM PCT/DO/EO/916 (371 Formalities Notice)

*50*

## STIC Biotechnology Systems Branch



### RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/522, 268  
Source: PCT  
Date Processed by STIC: 01/09/2006

**THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.**

**PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:**

- 1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
- 2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

**FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221**

**TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:**

**<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>**

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. **EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>) , EFS Submission User Manual - ePAVE)**
2. **U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**
3. **Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314**

Revised 01/10/06



## Raw Sequence Listing Error Summary


### ERROR DETECTED

### SUGGESTED CORRECTION

SERIAL NUMBER: 10/522, 268

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1  Wrapped Nucleics      The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2  Invalid Line Length      The rules require that a line **not exceed** 72 characters in length. This includes white spaces.
- 3  Misaligned Amino Numbering      The numbering under each 5<sup>th</sup> amino acid is misaligned. Do **not** use tab codes between numbers; use **space characters**, instead.
- 4  Non-ASCII      The submitted file was **not** saved in ASCII(DOS) text, as **required** by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5  Variable Length      Sequence(s) \_\_\_\_\_ contain n's or Xaa's representing more than one residue. **Per Sequence Rules, each n or Xaa can only represent a single residue.** Please present the **maximum** number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6  PatentIn 2.0 "bug"      A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) \_\_\_\_\_. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.**
- 7  Skipped Sequences (OLD RULES)      Sequence(s) \_\_\_\_\_ missing. If intentional, please insert the following lines for **each** skipped sequence:  
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
This sequence is intentionally skipped  
  
Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8  Skipped Sequences (NEW RULES)      Sequence(s) \_\_\_\_\_ missing. If intentional, please insert the following lines for **each** skipped sequence.  
<210> sequence id number  
<400> sequence id number  
000
- 9  Use of n's or Xaa's (NEW RULES)      Use of n's and/or Xaa's have been detected in the Sequence Listing.  
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10  Invalid <213> Response      Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is **required** when <213> response is Unknown or is Artificial Sequence
- 11  Use of <220>      Sequence(s) \_\_\_\_\_ missing the <220> "Feature" and associated numeric identifiers and responses.  
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12  PatentIn 2.0 "bug"      Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13  Misuse of n/Xaa      "n" can **only** represent a single nucleotide; "Xaa" can **only** represent a single amino acid



PCT

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/522,268

DATE: 01/09/2006  
TIME: 11:16:30

Input Set : A:\sequence listing.txt  
Output Set: N:\CRF4\01092006\J522268.raw

```

3 <110> APPLICANT: DAL POZZO, Alma
4      GIANNINI, Giuseppe
5      PISANO, Claudio
7 <120> TITLE OF INVENTION: Fluoro-Alkyl-Cyclopeptide Derivatives Endowed with
8      Anti-integrin Activity
10 <130> FILE REFERENCE: 2818-227
12 <140> CURRENT APPLICATION NUMBER: 10/522,268
13 <141> CURRENT FILING DATE: 2005-01-25
15 <150> PRIOR APPLICATION NUMBER: PCT/IT2003/000446
16 <151> PRIOR FILING DATE: 2003-07-18
18 <150> PRIOR APPLICATION NUMBER: ITRM2002A000402
19 <151> PRIOR FILING DATE: 2002-07-29
21 <160> NUMBER OF SEQ ID NOS: 1
23 <170> SOFTWARE: PatentIn Ver. 2.0
25 <210> SEQ ID NO: 1
26 <211> LENGTH: 6
27 <212> TYPE: PRT
28 <213> ORGANISM: Artificial Sequence
30 <220> FEATURE:
31 <221> NAME/KEY: VARIANT
32 <222> LOCATION: (4)
33 <223> OTHER INFORMATION: n = (R or S) Tfm
35 <220> FEATURE:
36 <223> OTHER INFORMATION: Description of Artificial Sequence:
37     circularmodified peptide
39 <400> SEQUENCE: 1
40 Arg Gly Asp Asn Phe Val
41     1           5

```

Does Not Comply  
Corrected Diskette Needed

(P8-1)

Invalid Response.

What is the source of  
genetic material?

Please see Item # 11 on  
Error Summary Sheet.



VERIFICATION SUMMARY

PATENT APPLICATION: US/10/522,268

DATE: 01/09/2006

TIME: 11:16:31

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\01092006\J522268.raw